Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Amadora – page 15

673 clinical trials in Amadora, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Amadora at a glance
673
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

673 trials in Amadora

Open in trial search

Neoplasm malignant+1

Recruiting

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Study on the Effectiveness of INCB000928 for Patients with Fibrodysplasia Ossificans Progressiva

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:INCB000928
  • Sponsor:Incyte Corp.

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Study to Test if Zelpultide Alfa Helps Prevent Lung Disease in High-Risk Premature Babies

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Recombinant Human Surfactant Protein-D
  • Sponsor:Airway Therapeutics Inc.

Study on Alisertib with Hormone Therapy for Patients with HR+, HER2- Recurrent or Metastatic Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Alisertib Sodium
  • Sponsor:Puma Biotechnology Inc.

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Breast cancer+4

Recruiting

Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Champalimaud Clinical Centre

Study on the Effectiveness of Oxaliplatin or Gemcitabine Chemotherapy in Patients with Resected Pancreatic Cancer Using Standard or Genetic Allocation Methods

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Amadora

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for HER2-positive and triple-negative variants. Research evaluates new therapeutic approaches for ovarian cancer and non-small cell lung cancer.

  • Chemotherapy-free treatments for HER2+ breast cancer
  • Advanced therapies for platinum-resistant ovarian cancer
  • Combination immunotherapy approaches

Multiple studies exploring targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Clinical research targeting systemic lupus erythematosus and related conditions. Studies evaluate novel treatments for scleroderma-related lung disease and inflammatory conditions.

  • Long-term safety studies for lupus treatments
  • Interstitial lung disease interventions
  • Novel therapeutic approaches for autoimmune disorders

Focus on developing safer and more effective treatments for chronic autoimmune conditions.

03 Cardiovascular and Metabolic Disorders

Research examining treatments for Type 2 diabetes with cardiovascular complications. Studies investigating new approaches for stroke prevention and vascular health.

  • Diabetes cardiovascular outcomes
  • Post-stroke treatment strategies
  • Vascular disease management

Comprehensive evaluation of therapeutic interventions for complex cardiometabolic conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.